The phase 3 trial will evaluate the efficacy of pemvidutide, a dual glucagon/GLP-1 receptor agonist, in metabolic dysfunction-associated steatohepatitis patients with moderate to advanced fibrosis, using an AI tool to standardize liver biopsy assessment.
David Chen, Pharm.D., of Kaiser Permanente discusses how PBM reform could speed biosimilar adoption and lower drug costs.
The real challenge for health plans isn’t simply deciding how to automate prior authorization but using this regulatory moment to build a far more durable cost-management strategy.
Phase 3 trials showed improvements in daytime wakefulness, cataplexy, and the disorder's full symptom range, including sleep paralysis and hallucinations.
New research in Menopause shows diabetic women face greater symptom burden during menopause transition, suggesting diabetes care should incorporate menopause symptom assessment and management.
Epic Research finds 2026 cholesterol guidelines and PREVENT-ASCVD expand statin eligibility to 54.6%, reshaping hyperlipidemia prevention and cardiovascular diseases risk.
Eric Levine, M.P.H., principal at Avalere Health, explains why a diagnosis alone won't exempt someone from the Medicaid work requirements that go into effect in 2027.
In June, the FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 in favor of Moderna’s mFlusiva, saying the benefits outweigh its risks for the prevention of influenza in adults older than 50.
Levine, a principal at Avalere Health, explains some of the details of Medicaid work requirements, including how activities of daily living may factor in and some of the leeway states have in how they are applied.
CMS's new interim rule sets an 80-hour monthly work requirement for many Medicaid enrollees but leaves states some latitude on setting medical exemptions and verification processes.
The finding is not novel, but it adds to the evidence base that atopic dermatitis makes people more susceptible to developing shingles.
A study by the American Diabetes Association also finds that 1.5 million diabetic Medicaid enrollees face new cost-sharing by 2029, potentially adding $1,000 in annual out-of-pocket costs in some states.
BeOne Medicines posts surging sales as Brukinsa leads blood cancer therapy growth, lifts 2026 outlook and adds new FDA approvals.
Melody Chang, RPh, BCOP, MBA, of the American Oncology Network, discusses building outpatient infrastructure for bispecific antibody and CAR-T therapy.
The researchers used efficiency frontier analysis, an alternative to quality-adjusted life years (QALYs), to rank adalimumab, secukinumab and bimekizumab, biologics used for hidradenitis suppurativa.
The Senate confirmed Erica Schwartz, M.D., J.D., M.P.H., 51-44, as CDC director, ending the agency's nearly year-long leadership vacancy.
Tufts researcher James Chambers, Ph.D., says IRA’s Medicare price negotiation program should target drugs that are unlikely to face biosimilar competition.
Journavx acute pain drug sees prescription surge as non-opioid coverage expands, lifting 2026 outlook and pain pipeline.
A mouse study found that formoterol was able to reduce liver fat, and a real-world analysis found that the asthma drug was associated with fewer complications from advanced liver disease and lower rates of several serious liver-related outcomes, including cirrhosis and all-cause mortality.
A South African trial found a doravirine-based HIV regimen caused less weight gain than a dolutegravir-based combination.
In an interview, James D. Chambers, Ph.D., from Tufts Medical Center, discusses how biosimilars have improved access to biologics, but more work needs to be done for patients to see cost reductions.
Genomic testing among Medicare beneficiaries with cancer rose from 6% in 2016 to 16.7% in 2023, though NGS use stayed low, a study found.
In this discussion, Mahavir Agarwal, M.D., Ph.D., a psychiatrist and scientist in the Schizophrenia Division at the Centre for Addiction and Mental Health (CAMH) in Toronto and an associate professor in the Department of Psychiatry at the University of Toronto, discusses recent advancements in treating antipsychotic-associated weight gain.
Yesafili joins Amgen's Pavblu as a competing Eylea biosimilar.
Pharmacy benefit managers are adopting new business models to adjust new transparency rules, but Holzworth-Nash says, "We're still focused on getting members to the right healthy outcomes. We’re still focused on empowering pharmacists. We are still focused on getting members to the lowest-cost therapies and helping members navigate their benefits.”
Patel says pharmacy benefit managers are better off using a low list price approach "because it’s simpler, it’s less opaque and, frankly, it’s more predictable.”
As she moved from specialty operations into broader benefit leadership roles, McMahan says her perspective changed, and she began to see the "whole board."
From her perch at Navitus, Crosson has become a prominent advocate on PBM transparency and prescription drug affordability issues, frequently speaking with policymakers, industry groups, and healthcare stakeholders about legislative reforms and regulatory trends.
Savasta welcomes the new transparency rules for pharmacy benefit managers because "transparency has always been a core component of our business model."
The move toward integrating HIV services with other healthcare services was already underway before the PEPFAR cuts, says Warren, executive director of AVAC.
